Ajulemic acid

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Ajulemic acid
Ajulemicacid.png
Clinical data
Trade namesLenabasum
Routes of
administration
Oral
ATC code
  • None
Legal status
Legal status
  • Investigational
Pharmacokinetic data
MetabolismMinimal
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC25H36O4
Molar mass400.559 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Ajulemic acid (AB-III-56, HU-239, IP-751, CPL 7075, CT-3, Anabasum) is a synthetic cannabinoid derivative of the THC metabolite 11-nor-9-carboxy-THC that shows anti-fibrotic and anti-inflammatory effects in pre-clinical studies without causing a subjective "high".[1] It is being developed for the treatment of inflammatory and fibrotic conditions such as systemic sclerosis, dermatomyositis and cystic fibrosis.[2] It does not share the anti-emetic effects of some other cannabinoids, but may be useful for treating chronic inflammatory conditions where inflammation fails to resolve.[3] Side effects include dry mouth, tiredness, and dizziness. The mechanism of action is through activation of the CB2 receptor leading to production of specialized proresolving eicosanoids such as lipoxin A4 and Prostaglandin J2. Studies in animals at doses up to 40 mg/kg show minimal psychoactivity of ajulemic acid, compared to that produced by tetrahydrocannabinol.[4] A composition of ajulemic acid named Lenabasum (formerly Anabasum, Resunab) is being developed by Corbus Pharmaceuticals (formerly JB Therapeutics) for the treatment of orphan chronic life-threatening inflammatory diseases.[5][citation needed]

References[edit]

  1. ^ Burstein, S.; Karst, M.; Schneider, U.; Zurier, R. (2004). "Ajulemic acid: A novel cannabinoid produces anti-inflammatory effects without a "high"". Life Sciences. 75 (12): 1513–1522. doi:10.1016/j.lfs.2004.04.010. PMID 15240185.
  2. ^ Mitchell, V.; Aslan, S.; Safaei, R.; Vaughan, C. (2005). "Effect of the cannabinoid ajulemic acid on rat models of neuropathic and inflammatory pain". Neuroscience Letters. 382 (3): 231–235. doi:10.1016/j.neulet.2005.03.019. PMID 15925096.
  3. ^ Burstein, S. (2005). "Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials". The AAPS Journal. 7 (1): E143–E148. doi:10.1208/aapsj070115. PMC 2751505. PMID 16146336.
  4. ^ Vann, R.; Cook, C.; Martin, B.; Wiley, J. (2007). "Cannabimimetic properties of ajulemic acid". The Journal of Pharmacology and Experimental Therapeutics. 320 (2): 678–686. doi:10.1124/jpet.106.111625. PMC 2633725. PMID 17105826.
  5. ^ "Companies To Watch: Corbus Pharmaceuticals". www.lifescienceleader.com. Retrieved 2019-05-20.